Kairos Pharma (NYSEAMERICAN:KAPA) Coverage Initiated at Maxim Group

Maxim Group assumed coverage on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research note published on Thursday morning,Benzinga reports. The firm issued a buy rating and a $4.00 target price on the stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price target on shares of Kairos Pharma in a research note on Thursday, March 20th.

Kairos Pharma Stock Down 5.0 %

Shares of KAPA opened at $0.92 on Thursday. Kairos Pharma has a 1 year low of $0.85 and a 1 year high of $4.00. The stock has a 50 day moving average price of $1.29.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.